Pharmacogenomics of breast cancer therapy: An updateKelly Westbrook, Vered Stearns|Pharmacology & Therapeutics|2013Cited by 49
Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuationKaren L. Smith, Vered Stearns, Daniela Jelovac et al.|npj Breast Cancer|2022Cited by 28
Abstract PS13-33: Feasibility of a comprehensive monitoring protocol for the prevention and treatment of interstitial lung disease in patients undergoing treatment with fam-trastuzumab deruxtecanHeather Moore, Kelly Westbrook, Scott Shofer et al.|Cancer Research|2021Cited by 4
Abstract P3-08-10: Characterization of oncotype DX recurrence score and chemotherapy utilization patterns in young women (≤40) with early stage ER+/HER-, lymph node negative breast cancerSarah Sammons, Rachel A. Greenup, Yi Ren et al.|Cancer Research|2020Cited by 3